Stockscreener 앱 받기
2.55
9.89%
-0.28
시간 외 거래:
2.55
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Fulcrum Therapeutics stock hits 52-week low at $2.77 - Investing.com India
Charles Schwab Investment Management Inc. Lowers Stock Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $8.63 - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FULC - Business Wire
Fulcrum Therapeutics stock hits 52-week low at $2.85 By Investing.com - Investing.com Australia
Fulcrum Therapeutics stock hits 52-week low at $2.85 - Investing.com India
Fulcrum Therapeutics at Leerink’s Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK
Investors who lost money on Fulcrum Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigationFULC - ACCESS Newswire
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal - Benzinga
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Fulcrum Therapeutics Ends Agreement with MyoKardia By Investing.com - Investing.com South Africa
Fulcrum Therapeutics Ends Agreement with MyoKardia - Investing.com India
Fulcrum Therapeutics Faces Termination of Key Agreement - TipRanks
Fulcrum Therapeutics Inc Myokardia Terminates Collaboration And License Agreement With Co - Marketscreener.com
Will Fulcrum Therapeutics Reveal New Rare Disease Pipeline Updates at Upcoming Leerink Conference? - StockTitan
Fulcrum Therapeutics (NASDAQ:FULC) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Leerink Partnrs Issues Negative Forecast for FULC Earnings - Defense World
HC Wainwright Has Pessimistic Outlook of FULC Q1 Earnings - Defense World
Fulcrum Therapeutics’ (FULC) Neutral Rating Reiterated at HC Wainwright - Defense World
Fulcrum Therapeutics' (FULC) Neutral Rating Reiterated at HC Wainwright - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Fulcrum Therapeutics, Inc. (FULC) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
What is HC Wainwright's Forecast for FULC FY2029 Earnings? - MarketBeat
FY2029 Earnings Estimate for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of “Hold” from Brokerages - Defense World
Fulcrum Therapeutics’ Earnings Call Highlights Financial Gains - TipRanks
Shareholder Rights Advocates at Levi & Korsinsky Investigate Fulcrum Therapeutics, Inc. (FULC) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Shareholders that lost money on Fulcrum Therapeutics, Inc. (FULC) should contact Levi & Korsinsky about Securities Fraud InvestigationFULC - ACCESS Newswire
Fulcrum Therapeutics (NASDAQ:FULC investor five-year losses grow to 82% as the stock sheds US$28m this past week - Simply Wall St
Lost Money on Fulcrum Therapeutics, Inc.(FULC)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2024 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 20 - GuruFocus.com
Fulcrum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FULCRUM THERAPEUTICS Earnings Results: $FULC Reports Quarterly Earnings - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 - The Manila Times
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics Reports Q4 and Full Year 2024 Financial Results and Updates on Pioneering SCD Trial - Nasdaq
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth - The Bakersfield Californian
Can Fulcrum's Improved Financials and Sickle Cell Trial Progress Attract Biotech Investors? - StockTitan
Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result - Yahoo Finance
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - Defense World
Fulcrum Therapeutics, Inc. Being Investigated on Behalf of Fulcrum Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Down 7.3% in January - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET - The Manila Times
Fulcrum Therapeutics, Inc. Scheduled to Release Q4 and Full Year 2024 Financial Results on February 25, 2025 - Nasdaq
Rare Disease Pioneer Fulcrum Sets Stage for Major 2024 Financial Revelation - StockTitan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement - Seeking Alpha
Fulcrum (FULC) Issues Strategic Employee Stock Options PackageKey Details Revealed - StockTitan
1.23%
1.63%
자본화:
|
볼륨(24시간):